Multiple Myeloma Resources
Chosen by Advanced
Practice Providers
  • Clinical guidelines
  • Patient support and education resources
  • Research updates

Increased Infection Risk With Bispecific Antibodies in Multiple Myeloma

Bispecific antibodies, a novel immunotherapy for multiple myeloma, create immune synapses between T-cell marker CD3 and malignant cell markers like B-cell maturation antigen (BCMA), FcRH5, and GPRC5D, effectively...
CURATED BY: Donna D. Catamero,
ANP-BC, OCN, CCRC

Advancements in CAR-T Therapy for RRMM Highlight Crucial Role of Nursing Professionals

The approval of chimeric antigen receptor T-cell (CAR-T) therapies for relapsed/refractory multiple myeloma (RRMM) has significantly advanced treatment options....
CURATED BY:
Laura J. Zitella,
MS, RN, ACNP-BC, AOCN

Efficacy of Daratumumab Regimens in Transplant-Eligible Patients With NDMM With High-Risk Cytogenetic Abnormalities

The MASTER study (NCT03224507) and GRIFFIN study (NCT02874742) evaluated the efficacy of daratumumab-containing regimens in transplant-eligible newly diagnosed patients with multiple myeloma (NDMM) with high-risk cytogenetic abnormalities (HRCAs)....
CURATED BY:
Danielle Roberts,
MS, MMSc, PA-C

Study Unveils Key Predictors of Success in BCMA CAR T Cell Therapy for Relapsed/Refractory Multiple Myeloma

B-cell maturation antigen (BCMA) -targeting CAR T cells have revolutionized the treatment of relapsed/refractory multiple myeloma....
CURATED BY:
Jill N. Burke,
CNP, DipACLM

Physician Associate and Nurse Practitioner Contributors to the Multiple Myeloma Center of Excellence

POCN’s Multiple Myeloma Center of Excellence is curated by practicing clinical physician associates and nurse practitioners who review and select resources that are the most useful to their peers. They provide their expertise by hand-picking the latest content for advanced practice providers.

Provided by an unrestricted grant from

Share